University of Groningen: UMCG and UG to take part in European project on accelerating vaccine development

A multidisciplinary team of researchers from 11 different countries are starting a project on speeding up the development of vaccines. Researchers from the University of Groningen (UG) and the University Medical Center Groningen (UMCG) will study whether miniature lungs (‘mini-lungs’) can be deployed in a propagator to predict which vaccines work well against respiratory infections such as the flu.

Vaccine development: time-consuming and expensive
An estimated 2.5 million lives are saved each year and millions of people are protected from illness and disability because of vaccines. The coronavirus pandemic has shown us how important it is to be able to respond quickly to dangerous pathogens. However, the time lines needed to research and develop classic vaccines are long and costly. On average, it takes over 10 years to launch a new vaccine on the market – at a cost of more than €800 million.

Interdisciplinary project
A large, interdisciplinary project has been set up to change this state of affairs. By designing and applying advanced new models of human organs, it should be possible to develop and produce vaccines more quickly.

Mini-lungs in a propagator
The Department of Medical Microbiology & Infection Prevention at the UMCG and the Department of Molecular Pharmacology at the Groningen Research Institute of Pharmacy will jointly participate in the project. Together, they will research whether mini-lungs can be deployed in a propagator to predict which vaccines work well against respiratory infections such as the flu.

The project, Inno4vac, is a public-private partnership, jointly financed by the EU and vaccine producers, which is being coordinated by the European Vaccine Initiative in Germany. In total, there are 41 project partners from 11 different European countries. A total of €33 million has been set aside for the project.

Comments are closed.